{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:47Z","timestamp":1787671907218,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13774-w","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:35:42Z","timestamp":1781606142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High frequency of HIV-1 drug resistance among individuals with persistent low-level viremia during first-line antiretroviral therapy in Uganda"],"prefix":"10.1186","volume":"26","author":[{"given":"Grace","family":"Sanyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunia","family":"Mayanja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah","family":"Omooja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet Nkugwa","family":"Asio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nannyonjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ssemanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nansumba","family":"Hellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Ssewanyana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kato Charles","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deogratius","family":"Ssemwanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"13774_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics - fact sheet | UNAIDS. 2025. Available at: https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 13 Sept 2025."},{"key":"13774_CR2","unstructured":"NIH. HIV treatment: the basics | NIH. 2024. Available at: https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/hiv-treatment-basics. Accessed 31 Oct 2024."},{"issue":"1","key":"13774_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/QCO.0000000000000613","volume":"33","author":"BR Bavinton","year":"2020","unstructured":"Bavinton BR, Rodger AJ. Undetectable viral load and HIV transmission dynamics on an individual and population level: where next in the global HIV response? Curr Opin Infect Dis. 2020;33(1):20. Available at: https:\/\/doi.org\/10.1097\/QCO.0000000000000613. https:\/\/journals.lww.com\/co-infectiousdiseases\/abstract\/2020\/02000\/undetectable_viral_load_and_hiv_transmission.4.aspx. Accessed 20 Nov 2024.","journal-title":"Curr Opin Infect Dis"},{"key":"13774_CR4","unstructured":"European Centre for Disease Prevention and Control. The benefits of HIV treatment: undetectable means you do not pass on the virus. 2018. Available at: https:\/\/www.ecdc.europa.eu\/en\/news-events\/benefits-hiv-treatment-undetectable-means-you-do-not-pass-virus. Accessed 31 Oct 2024."},{"issue":"04","key":"13774_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4172\/2155-6113.1000565","volume":"7","author":"E Paintsil","year":"2016","unstructured":"Paintsil E, Martin R. Frequent episodes of detectable viremia in HIV treatment-experienced children is associated with a decline in CD4+ T-cells over time. J AIDS Clin Res. 2016;7(04):565. Available at: https:\/\/doi.org\/10.4172\/2155-6113.1000565. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4929848\/. Accessed 19 Nov 2024.","journal-title":"J AIDS Clin Res"},{"key":"13774_CR6","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection: recommendations for a Public health approach. 2016. Available at: http:\/\/www.deslibris.ca\/ID\/10089566. Accessed 9 Oct 2018."},{"issue":"9","key":"13774_CR7","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3390\/v16091454","volume":"16","author":"M Nannyonjo","year":"2024","unstructured":"Nannyonjo M, Omooja J, Bugembe DL, Bbosa N, Lunkuse S, Nabirye SE, et al. Next-generation sequencing reveals a high Frequency of HIV-1 minority variants and an expanded drug resistance profile among individuals on first-line ART. Viruses. 2024;16(9):1454. Available at: https:\/\/doi.org\/10.3390\/v16091454. https:\/\/www.mdpi.com\/1999-4915\/16\/9\/1454. Accessed 21 Nov 2024.","journal-title":"Viruses"},{"key":"13774_CR8","unstructured":"Kantor R, Delong A, Schreier L, et al. HIV second-line failure and drug resistance at high- and low-level viremia in Western Kenya: aIDS. 2018:1. Available at: http:\/\/Insights.ovid.com\/crossref?an=00002030-900000000-97112. Accessed 18 Oct 2018."},{"key":"13774_CR9","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1080\/21505594.2021.2004743","volume":"12","author":"C Crespo-Bermejo","year":"2021","unstructured":"Crespo-Bermejo C, de Arellano ER, Lara-Aguilar V, et al. Persistent low-level viremia in persons living with HIV undertreatment: an unresolved status. Virulence. 2021;12:2919\u201331. Available at: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21505594.2021.2004743. Accessed 19 Nov 2024.","journal-title":"Virulence"},{"key":"13774_CR10","unstructured":"World Health Organisation. Consolidated guidelines on HIV, viral hepatitis and STI Prevention, diagnosis, treatment and care for Key populations. 1st. Geneva: World Health Organization; 2022."},{"key":"13774_CR11","unstructured":"EACS. European AIDS clinical society. 2023. Available at: https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf. Accessed 6 Feb 2026."},{"key":"13774_CR12","unstructured":"Ugandan Ministry of Health. Consolidated guidelines for the prevention and treatment of of HIV and AIDS in Uganda. 2022. Available at: https:\/\/dsduganda.com\/wp-content\/uploads. Accessed 29 Jul 2024."},{"key":"13774_CR13","doi-asserted-by":"crossref","unstructured":"The Antiretroviral Therapy Cohort Collaboration (ART-CC) TATC, Vandenhende, M-A. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 2015;29:373. Available at: https:\/\/journals.lww.com\/aidsonline\/abstract\/2015\/01280\/impact_of_low_level_viremia_on_clinical_and.13.aspx. Accessed 19 Nov 2024.","DOI":"10.1097\/QAD.0000000000000544"},{"issue":"1","key":"13774_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12879-023-08906-5","volume":"24","author":"X Lao","year":"2024","unstructured":"Lao X, Zhang H, Deng M, Li Q, Xiao Q, He L, et al. Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study. BMC Infect Dis. 2024;24(1):8. Available at: https:\/\/doi.org\/10.1186\/s12879-023-08906-5. Accessed 19 Nov 2024.","journal-title":"BMC Infect Dis"},{"key":"13774_CR15","doi-asserted-by":"publisher","first-page":"104255","DOI":"10.1016\/j.jcv.2019.104255","volume":"123","author":"L Taramasso","year":"2020","unstructured":"Taramasso L, Magnasco L, Bruzzone B, Caligiuri P, Bozzi G, Mora S, et al. How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis. J Clin Virol. 2020;123:104255. Available at: https:\/\/doi.org\/10.1016\/j.jcv.2019.104255. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1386653219302859. Accessed 7 Feb 2026.","journal-title":"J Clin Virol"},{"key":"13774_CR16","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.4102\/ajlm.v11i1.1899","volume":"11","author":"N Nanyeenya","year":"2022","unstructured":"Nanyeenya N, Kiwanuka N, Nakanjako D, et al. Low-level viraemia: an emerging concern among people living with HIV in Uganda and across sub-Saharan Africa. Afr J Lab Med. 2022;11:1899. Available at: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9639359\/. Accessed 6 Feb 2026.","journal-title":"Afr J Lab Med"},{"key":"13774_CR17","doi-asserted-by":"crossref","unstructured":"Aoko A, Pals S, Ngugi T, et al. Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya. eClinicalmedicine. 2023:63. Available at: https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(23)00343-7\/fulltext. Accessed 19 Nov 2024.","DOI":"10.1016\/j.eclinm.2023.102166"},{"key":"13774_CR18","doi-asserted-by":"crossref","unstructured":"Nka AD, Fokam J, Chenwi CA, et al. PA-352 detectable low-level viremia among people living with HIV in Cameroon suggests a revised threshold for viral suppression: evidence in the era of dolutegravir-based ART. BMJ glob health. 2023:8. https:\/\/gh.bmj.com\/content\/8\/Suppl_10\/A68.2. Accessed 19 Nov 2024.","DOI":"10.1136\/bmjgh-2023-EDC.168"},{"key":"13774_CR19","doi-asserted-by":"crossref","unstructured":"Chun HM, Abutu A, Milligan K, Ehoche A, Shiraishi RW, Odafe S, et al. Low-level viraemia among people living with HIV in Nigeria: a retrospective longitudinal cohort study. LancetThe Lancet Global Health. 2022;10(12):e1815\u201324. Available at: https:\/\/doi.org\/10.1016\/S2214-109X(22)00413-2. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214109X22004132. Accessed 18 Nov 2024.","DOI":"10.1016\/S2214-109X(22)00413-2"},{"key":"13774_CR20","doi-asserted-by":"publisher","unstructured":"Esber A, Polyak C, Kiweewa F, et al. Persistent low-level viremia predicts subsequent virologic failure: is it time to change the Third 90? Clin Infect Dis. 2019;69:805\u201312. Available at: https:\/\/doi.org\/10.1093\/cid\/ciy989. Accessed 19 Nov 2024.","DOI":"10.1093\/cid\/ciy989"},{"key":"13774_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/cid\/ciac762","volume":"76","author":"O Elvstam","year":"2023","unstructured":"Elvstam O, Malmborn K, El\u00e9n S, et al. Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort. Clin Infect Dis. 2023;76:25\u201331. Available at: https:\/\/doi.org\/10.1093\/cid\/ciac762. Accessed 19 Nov 2024.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"13774_CR22","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/cid\/ciz129","volume":"69","author":"C Joya","year":"2019","unstructured":"Joya C, Won SH, Schofield C, Lalani T, Maves RC, Kronmann K, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk Factor for virologic failure. Clin Infect Dis. 2019;69(12):2145\u201352. Available at: https:\/\/doi.org\/10.1093\/cid\/ciz129. Accessed 19 Nov 2024.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"13774_CR23","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","volume":"28","author":"LC Swenson","year":"2014","unstructured":"Swenson LC, Min JE, Woods CK, Cai E, Li JZ, Montaner JSG, et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS Lond Engl. 2014;28(8):1125. Available at: https:\/\/doi.org\/10.1097\/QAD.0000000000000203. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4278403\/. Accessed 19 Nov 2024.","journal-title":"AIDS Lond Engl"},{"issue":"8","key":"13774_CR24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/cid\/ciu019","volume":"58","author":"A Gonzalez-Serna","year":"2014","unstructured":"Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JSG, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58(8):1165\u201373. Available at: https:\/\/doi.org\/10.1093\/cid\/ciu019. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3967823\/. Accessed 11 Oct 2020.","journal-title":"Clin Infect Dis"},{"key":"13774_CR25","unstructured":"WHO. HIV drug resistance report 2021. 1st ed. Geneva: World Health Organization; 2021. Available at: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/a76922b0-6ee8-4c39-a17a-30c51f4869d0\/content. Accessed 6 Feb 2026."},{"issue":"9","key":"13774_CR26","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1093\/jac\/dkab159","volume":"76","author":"C Watera","year":"2021","unstructured":"Watera C, Ssemwanga D, Namayanja G, Asio J, Lutalo T, Namale A, et al. HIV drug resistance among adults initiating antiretroviral therapy in Uganda. The J Antimicrob Chemother. 2021;76(9):2407\u201314. Available at: https:\/\/doi.org\/10.1093\/jac\/dkab159. https:\/\/academic.oup.com\/jac\/article\/76\/9\/2407\/6276545. Accessed 10 Oct 2021.","journal-title":"The J Antimicrob Chemother"},{"issue":"5","key":"13774_CR27","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/jac\/dkz561","volume":"75","author":"D Ssemwanga","year":"2020","unstructured":"Ssemwanga D, Asio J, Watera C, Nannyonjo M, Nassolo F, Lunkuse S, et al. Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda. J Antimicrob Chemother. 2020;75(5):1280\u201389. Available at: https:\/\/doi.org\/10.1093\/jac\/dkz561. https:\/\/academic.oup.com\/jac\/article\/75\/5\/1280\/5727896. Accessed 11 Oct 2020.","journal-title":"The J Antimicrob Chemother"},{"key":"13774_CR28","doi-asserted-by":"publisher","unstructured":"Kaleebu P, Kirungi W, Watera C, Asio J, Lyagoba F, Lutalo T, et al. Virological response and antiretroviral drug resistance emerging during antiretroviral therapy at Three treatment centers in Uganda. PLoS One. 2015;10(12):e0145536. Available at: https:\/\/doi.org\/10.1371\/journal.pone.0145536. http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0145536. Accessed 4 Sept 2017.","DOI":"10.1371\/journal.pone.0145536"},{"issue":"10","key":"13774_CR29","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/jac\/dkz261","volume":"74","author":"J Omooja","year":"2019","unstructured":"Omooja J, Nannyonjo M, Sanyu G, Nabirye SE, Nassolo F, Lunkuse S, et al. Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda. J Antimicrob Chemother. 2019;74(10):3021\u201329. Available at: https:\/\/doi.org\/10.1093\/jac\/dkz261. https:\/\/academic.oup.com\/jac\/article\/74\/10\/3021\/5525340. Accessed 12 Oct 2020.","journal-title":"The J Antimicrob Chemother"},{"key":"13774_CR30","unstructured":"NIH. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Clinicalinfo. 2024. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/virologic-failure. Accessed 20 Nov 2024."},{"issue":"6","key":"13774_CR31","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1128\/JCM.06689-11","volume":"50","author":"CK Woods","year":"2012","unstructured":"Woods CK, Brumme CJ, Liu TF, Chui CKS, Chu AL, Wynhoven B, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol. 2012;50(6):1936\u201342. Available at: https:\/\/doi.org\/10.1128\/JCM.06689-11. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3372133\/. Accessed 6 Feb 2026.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"13774_CR32","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/bioinformatics\/btu033","volume":"30","author":"A Stamatakis","year":"2014","unstructured":"Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics. 2014;30(9):1312\u201313. Available at: https:\/\/doi.org\/10.1093\/bioinformatics\/btu033. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3998144\/. Accessed 25 Feb 2020.","journal-title":"Bioinformatics"},{"issue":"11","key":"13774_CR33","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"TF Liu","year":"2006","unstructured":"Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608\u201318. Available at: https:\/\/doi.org\/10.1086\/503914. https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1086\/503914. Accessed 7 Feb 2019.","journal-title":"Clin Infect Dis"},{"key":"13774_CR34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s12879-022-07453-9","volume":"22","author":"J Omooja","year":"2022","unstructured":"Omooja J, Bbosa N, Lule DB, et al. HIV-1 drug resistance genotyping success rates and correlates of dried-blood spots and plasma specimen genotyping failure in a resource-limited setting. BMC Infect Dis. 2022;22:474. Available at: https:\/\/doi.org\/10.1186\/s12879-022-07453-9. Accessed 21 Nov 2024.","journal-title":"BMC Infect Dis"},{"key":"13774_CR35","doi-asserted-by":"crossref","unstructured":"Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, et al. Impact of low-level-viremia on HIV-1 drug-resistance Evolution among antiretroviral treated-patients. PLoS One. 2012;7(5):e36673. Available at: https:\/\/doi.org\/10.1371\/journal.pone.0036673. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3349708\/. Accessed 19 Nov 2024.","DOI":"10.1371\/journal.pone.0036673"},{"issue":"4","key":"13774_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/jpids\/piy041","volume":"8","author":"R Pereira","year":"2019","unstructured":"Pereira R, Ludwig DA, Mathew S, Flores C, Dominguez S, Gonzalez I, et al. Predicting viral failure in human immunodeficiency Virus perinatally infected youth with Persistent low-level viremia on highly active antiretroviral therapy. J Educ Chang Pediatr Infect Dis Soc. 2019;8(4):303\u201309. Available at: https:\/\/doi.org\/10.1093\/jpids\/piy041. Accessed 19 Nov 2024.","journal-title":"J Educ Chang Pediatr Infect Dis Soc"},{"issue":"1","key":"13774_CR37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12879-022-07417-z","volume":"22","author":"P Liu","year":"2022","unstructured":"Liu P, You Y, Liao L, Feng Y, Shao Y, Xing H, et al. Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China. BMC Infect Dis. 2022;22(1):426. Available at: https:\/\/doi.org\/10.1186\/s12879-022-07417-z. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9066819\/. Accessed 6 Feb 2026.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"13774_CR38","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1089\/aid.2019.0279","volume":"36","author":"F Segujja","year":"2020","unstructured":"Segujja F, Omooja J, Lunkuse S, Nanyonjo M, Nabirye SE, Nassolo F, et al. High levels of acquired HIV drug resistance following virological nonsuppression in HIV-Infected women from a high-risk cohort in Uganda. Aids Res Hum Retrov. 2020;36(9):782\u201391. Available at: https:\/\/doi.org\/10.1089\/aid.2019.0279. https:\/\/login.research4life.org\/tacsgr1www_liebertpub_com\/doi\/10.1089\/aid.2019. Accessed 12 Oct 2020.","journal-title":"Aids Res Hum Retrov"},{"key":"13774_CR39","unstructured":"WHO. Preventing and responding to HIV drug-resistance in the African region: regional action plan 2019-2023. Brazzaville, Congo: World Health Organization. Regional Office for Africa. 2019. Available at: https:\/\/www.afro.who.int\/sites\/default\/files\/2019-04\/HIV_DrugRes_FINAL_01_04_19_online.pdf. Accessed 20 Mar 2023."},{"issue":"2","key":"13774_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.2016.8900","volume":"316","author":"HF G\u00fcnthard","year":"2016","unstructured":"G\u00fcnthard HF, Saag MS, Benson CA, Del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral Drugs for treatment and Prevention of HIV Infection in adults. JAMA. 2016;316(2):191\u2013210. Available at: https:\/\/doi.org\/10.1001\/jama.2016.8900. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5012643\/. Accessed 6 Feb 2026.","journal-title":"JAMA"},{"key":"13774_CR41","unstructured":"WHO. HIV drug resistance: brief report 2024. 2024. Available at: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/b9c5dba5-4055-46e3-ab42-abdd00f94aa5\/content. Accessed 6 Feb 2026."},{"issue":"1","key":"13774_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12981-020-00294-z","volume":"17","author":"J Nega","year":"2020","unstructured":"Nega J, Taye S, Million Y, Rodrigo C, Eshetie S. Antiretroviral treatment failure and associated factors among HIV patients on first-line antiretroviral treatment in Sekota, northeast Ethiopia. AIDS Res Ther. 2020;17(1):39. Available at: https:\/\/doi.org\/10.1186\/s12981-020-00294-z. Accessed 12 Oct 2021.","journal-title":"AIDS Res Ther"},{"key":"13774_CR43","doi-asserted-by":"crossref","unstructured":"Wagner Z, Wang Z, Stecher C, Karamagi Y, Odiit M, Haberer JE, et al. The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda. J Int AIDS Soc. 2024;27(8):e26350. Available at: https:\/\/doi.org\/10.1002\/jia2.26350. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11330848\/. Accessed 16 May 2026.","DOI":"10.1002\/jia2.26350"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13774-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13774-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13774-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:06:31Z","timestamp":1787670391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13774-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13774"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13774-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7736362\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Helsinki declaration. Ethical approval to conduct this study was provided by the Uganda Virus Research Institute Research and Ethics Committee (UVRI REC-reference number GC\/127\/20\/05\/428), and the Uganda National Council for Science and Technology (UNCST) under reference number HS 1432. Informed consent to participate in the study was obtained from all participants, who also provided informed consent to storage, and to the use of their samples for future HIV-related research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1558"}}